Vigil Neuroscience Inc (VIGL)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| CEO: | Ivana Magovcevic-Liebisch |
| Employees: | 40 |
| Web site: | vigilneuro.com |
|
100 FORGE ROAD, SUITE 700, WATERTOWN, MA, 02472
857-254-4445
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Vigil Neuroscience, Inc. engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) The company also develops a small molecule TREM2 agonist suitable for oral delivery.
Please log in first to see chart